Cemiplimab-rwlc is also approved for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score ≥50%) and no epidermal growth factor receptor, anaplastic lymphoma kinase or ROS1 aberrations, for patients with metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.